SCHEMBL6016025

SCHEMBL6016025

CC(=O)OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS1 P23219 1/20 0.40
▸ PTGS2 P35354 1/20 0.40
▸ SLC2A1 P11166 1/20 0.40
▸ PRKD3 O94806 1/20 0.39
▸ PRKCG P05129 1/20 0.39
▸ PRKCB P05771 1/20 0.39
▸ PRKCA P17252 1/20 0.39
▸ PRKCH P24723 1/20 0.39
▸ PRKCI P41743 1/20 0.39
▸ PRKCE Q02156 1/20 0.39
▸ PRKCQ Q04759 1/20 0.39
▸ PRKCZ Q05513 1/20 0.39
▸ PRKCD Q05655 1/20 0.39
▸ PRKD1 Q15139 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ THRB P10828 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ TSHR P16473 1/20 0.38
▸ NR3C1 P04150 1/20 0.38
▸ FYN P06241 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9521214 1.00 PTGS1 (0.40) PTGS1PTGS2SLC2A1PRKD3PRKCG
SCHEMBL7163178 1.00 PTGS1 (0.40) PTGS1PTGS2SLC2A1PRKD3PRKCG
SCHEMBL15201698 1.00 PTGS1 (0.40) PTGS1PTGS2SLC2A1PRKD3PRKCG
SCHEMBL7720721 1.00 PTGS1 (0.40) PTGS1PTGS2SLC2A1PRKD3PRKCG
SCHEMBL15963880 1.00 PTGS1 (0.40) PTGS1PTGS2SLC2A1PRKD3PRKCG
SCHEMBL6015980 1.00 PTGS1 (0.40) PTGS1PTGS2SLC2A1PRKD3PRKCG
SCHEMBL8668910 1.00 PTGS1 (0.40) PTGS1PTGS2SLC2A1PRKD3PRKCG
SCHEMBL9521223 1.00 PTGS1 (0.40) PTGS1PTGS2SLC2A1PRKD3PRKCG
SCHEMBL9563973 1.00 PTGS1 (0.40) PTGS1PTGS2SLC2A1PRKD3PRKCG
SCHEMBL12427214 1.00 PTGS1 (0.40) PTGS1PTGS2SLC2A1PRKD3PRKCG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1735327-A1 AN IMPROVED PROCESS FOR PRODUCING CHLORINATED SUCROSE Pharmed Medicare Private Limited (IN) 2006-12-27 — — EP disclosed
WO-2005090374-A1 AN IMPROVED PROCESS FOR PRODUCING CHLORINATED SUCROSE PHARMED MEDICARE PRIVATE LIMITED (IN) 2005-09-29 — — WO disclosed
US-20040132705-A1 Inhibitors of thromboxane formation and action APAC PHARMA LLC 2004-07-08 — — US disclosed
WO-2002038157-A2 INHIBITORS OF THROMBOXANE FORMATION AND ACTION THE HOSPITAL FOR SICK CHILDREN (CA) 2002-05-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040132705-A1 Inhibitors of thromboxane formation and action PLAT, TBXAS1, TBXA2R PTGS1 48/4885PTGS2 58/4885SLC2A1 3276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback